Hamdi Sati

1.0k total citations
9 papers, 229 citations indexed

About

Hamdi Sati is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Hamdi Sati has authored 9 papers receiving a total of 229 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Hamdi Sati's work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (3 papers) and Peptidase Inhibition and Analysis (2 papers). Hamdi Sati is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (3 papers) and Peptidase Inhibition and Analysis (2 papers). Hamdi Sati collaborates with scholars based in United Kingdom, United States and Australia. Hamdi Sati's co-authors include M. Greaves, R.G.G. Russell, Peter I. Croucher, Heather Watson, Dominic Culligan, Stuart H. Ralston, M. Greaves, Richard Soutar, Sharon Gordon and Miep Helfrich and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Haematology and Thrombosis and Haemostasis.

In The Last Decade

Hamdi Sati

9 papers receiving 219 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hamdi Sati United Kingdom	5	160	138	74	32	26	9	229
Raphael Teipel Germany	8	137 0.9×	72 0.5×	59 0.8×	30 0.9×	12 0.5×	21	196
Daniel Egan United States	8	127 0.8×	123 0.9×	79 1.1×	49 1.5×	16 0.6×	22	212
Shayu Deshpande United States	9	117 0.7×	59 0.4×	113 1.5×	48 1.5×	9 0.3×	17	215
Sung‐Soo Yoon South Korea	9	152 0.9×	91 0.7×	120 1.6×	35 1.1×	12 0.5×	54	272
Yongsheng Ruan China	9	116 0.7×	73 0.5×	68 0.9×	29 0.9×	6 0.2×	32	239
Max Bittrich Germany	9	109 0.7×	130 0.9×	101 1.4×	57 1.8×	10 0.4×	20	243
Peter Tan Australia	10	126 0.8×	55 0.4×	109 1.5×	85 2.7×	12 0.5×	18	252
Elizabeth Budde United States	9	88 0.6×	161 1.2×	105 1.4×	48 1.5×	30 1.2×	26	275
Carmen Martínez‐Chamorro Spain	9	341 2.1×	173 1.3×	128 1.7×	38 1.2×	19 0.7×	15	383
Andrea Zangrando Italy	8	123 0.8×	95 0.7×	147 2.0×	25 0.8×	8 0.3×	9	303

Countries citing papers authored by Hamdi Sati

Since Specialization

Citations

This map shows the geographic impact of Hamdi Sati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamdi Sati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamdi Sati more than expected).

Fields of papers citing papers by Hamdi Sati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hamdi Sati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamdi Sati. The network helps show where Hamdi Sati may publish in the future.

Co-authorship network of co-authors of Hamdi Sati

This figure shows the co-authorship network connecting the top 25 collaborators of Hamdi Sati. A scholar is included among the top collaborators of Hamdi Sati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hamdi Sati. Hamdi Sati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Cook, Gordon, A. John Ashcroft, Catherine Olivier, et al.. (2024). Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology. 11(11). e816–e829. 1 indexed citations

Dimopoulos, Meletios Α., Fredrik Schjesvold, Vadim Doronin, et al.. (2022). Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial. Blood Cancer Journal. 12(1). 9–9. 15 indexed citations

Dimopoulos, Meletios Α., Fredrik Schjesvold, Vadim Doronin, et al.. (2021). Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.. Journal of Clinical Oncology. 39(15_suppl). 8020–8020. 1 indexed citations

Bowen, D. J., et al.. (2006). Cefotaxime as the potential cause of transient acquired von Willebrand syndrome. European Journal Of Haematology. 76(5). 440–443. 2 indexed citations

Gordon, Sharon, Miep Helfrich, Hamdi Sati, et al.. (2002). Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. British Journal of Haematology. 119(2). 475–483. 54 indexed citations

Sati, Hamdi, et al.. (2001). Incidence and associations of acute renal failure complicating high‐dose intravenous immunoglobulin therapy. British Journal of Haematology. 113(2). 556–557. 44 indexed citations

Sati, Hamdi, et al.. (1999). Expression of interleukin‐1β and tumour necrosis factor‐α in plasma cells from patients with multiple myeloma. British Journal of Haematology. 104(2). 350–357. 79 indexed citations

Sati, Hamdi, M. Greaves, J Lawry, et al.. (1998). Interleukin‐6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. British Journal of Haematology. 101(2). 287–295. 30 indexed citations

Sati, Hamdi, et al.. (1998). Recurrent Adenocarcinoma of Prostate Presenting as Acquired Haemophilia A. Thrombosis and Haemostasis. 80(12). 1034–1034. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact